ArticleJournal of neurovirology2007
Evidence for human herpesvirus 6 variant A antibodies in multiple sclerosis: diagnostic and therapeutic implications.
Article in Journal of neurovirology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis.Brain : a journal of neurology · 2024Article
- The Probable Infectious Origin of Multiple Sclerosis.NeuroSci · 2023Review
- Mouse Models for Human Herpesviruses.Pathogens (Basel, Switzerland) · 2023Review
- Human Herpesvirus 6A Is a Risk Factor for Multiple Sclerosis.Frontiers in immunology · 2022Review
- The Combination of gQ1 and gQ2 in Human Herpesvirus 6A and 6B Regulates the Viral Tetramer Function for Their Receptor Recognition.Journal of virology · 2021Article
- Human Herpesvirus 6A Induces Dendritic Cell Death and HMGB1 Release without Virus Replication.Pathogens (Basel, Switzerland) · 2021Article
- The role of herpesvirus 6A and 6B in multiple sclerosis and epilepsy.Scandinavian journal of immunology · 2020Review
- Prevalence of seropositivity of selected herpesviruses in patients with multiple sclerosis in the North of Jordan.BMC neurology · 2020Article
- Search for viral agents in cerebrospinal fluid in patients with multiple sclerosis using real-time PCR and metagenomics.PloS one · 2020Article
- Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls.Multiple sclerosis (Houndmills, Basingstoke, England) · 2019Article
- Increased Serological Response Against Human Herpesvirus 6A Is Associated With Risk for Multiple Sclerosis.Frontiers in immunology · 2019Article
- Neural Stem Cell-Based Regenerative Approaches for the Treatment of Multiple Sclerosis.Molecular neurobiology · 2018Review
- Recent developments in animal models for human herpesvirus 6A and 6B.Current opinion in virology · 2014Review
- Oligoclonal bands in multiple sclerosis reactive against two herpesviruses and association with magnetic resonance imaging findings.Multiple sclerosis (Houndmills, Basingstoke, England) · 2014Article
- Human herpesvirus 6A infection and immunopathogenesis in humanized Rag2⁻/⁻ γc⁻/⁻ mice.Journal of virology · 2013Article
- Immunopathological patterns from EAE and Theiler's virus infection: Is multiple sclerosis a homogenous 1-stage or heterogenous 2-stage disease?Pathophysiology : the official journal of the International Society for Pathophysiology · 2013Article
- Viruses and multiple sclerosis.CNS & neurological disorders drug targets · 2012Review
- Human herpesvirus 6 infection as a trigger of multiple sclerosis.Mayo Clinic proceedings · 2010Review
- Potential triggers of MS.Results and problems in cell differentiation · 2010Review
- Chronic viral infections of the central nervous system: Aspects specific to multiple sclerosis.Revue neurologique · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human herpesvirus 6 (HHV-6) has been linked to the pathogenesis of multiple sclerosis (MS). HHV-6 antibodies in serum and cerebrospinal fluid (CSF) of 27 patients with clinically definite MS (CDMS) were compared with age- and sex-matched controls, including various other neurological diseases and symptoms (OND). In addition, we studied a series of 19 patients with clinically or laboratory supported possible MS (CPMS). Seroprevalence to HHV-6A was 100% in patients with MS, both in CDMS and CPMS, compared to 69.2% in patients with OND (P = .001 and .007). The mean immunoglobulin G (IgG) titers were significantly higher in patients with CDMS and CPMS than in controls (P = .005 and .00002). The proportion of acute primary infections without CSF involvement was similar in all groups; however, primary infections with intrathecal HHV-6 antibody production were more frequent in MS. In CSF, HHV-6A-specific antibodies were present in three (11.5%) and four (21.1%) patients with CDMS and CPMS, compared to none with OND (P = .06 and .01, respectively). Serological suggestions to HHV-6A infection occurred more often in both CDMS and CPMS than in OND (14.8% versus 21.1% versus 3.8%). We conclude that a subpopulation of MS patients, and even a greater proportion of possible MS subjects, has serological evidence of HHV-6A infection, which might provide new markers for diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.